163 related articles for article (PubMed ID: 28216622)
21. A phase II multicenter randomized controlled trial to compare standard chemoradiation with or without recombinant human endostatin injection (Endostar) therapy for the treatment of locally advanced nasopharyngeal carcinoma: Long-term outcomes update.
Li Y; Tian Y; Jin F; Wu W; Long J; Ouyang J; Zhou Y
Curr Probl Cancer; 2020 Feb; 44(1):100492. PubMed ID: 32035692
[TBL] [Abstract][Full Text] [Related]
22. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched study.
Guo SS; Tang LQ; Chen QY; Zhang L; Liu LT; Guo L; Mo HY; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Wang L; Lv X; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
Oncotarget; 2016 May; 7(20):29739-48. PubMed ID: 27105538
[TBL] [Abstract][Full Text] [Related]
23. The Role of Intravoxel Incoherent Motion MRI in Predicting Early Treatment Response to Chemoradiation for Metastatic Lymph Nodes in Nasopharyngeal Carcinoma.
Lu L; Li Y; Li W
Adv Ther; 2016 Jul; 33(7):1158-68. PubMed ID: 27294489
[TBL] [Abstract][Full Text] [Related]
24. Radiotherapy with neoadjuvant chemotherapy versus concurrent chemoradiotherapy for ascending-type nasopharyngeal carcinoma: a retrospective comparison of toxicity and prognosis.
Yao JJ; Yu XL; Zhang F; Zhang WJ; Zhou GQ; Tang LL; Mao YP; Chen L; Ma J; Sun Y
Chin J Cancer; 2017 Mar; 36(1):26. PubMed ID: 28264724
[TBL] [Abstract][Full Text] [Related]
25. Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter randomized controlled study.
Lu Y; Chen D; Liang J; Gao J; Luo Z; Wang R; Liu W; Huang C; Ning X; Liu M; Huang H
BMC Cancer; 2019 Dec; 19(1):1262. PubMed ID: 31888551
[TBL] [Abstract][Full Text] [Related]
26. Tumor regression patterns by follow-up duration in patients with nasopharyngeal carcinoma treated with concurrent chemoradiotherapy.
Kong M; Hong SE
J Radiat Res; 2017 Mar; 58(2):232-237. PubMed ID: 27738079
[TBL] [Abstract][Full Text] [Related]
27. Comparison of radiotherapy combined with nimotuzumab vs. chemoradiotherapy for locally recurrent nasopharyngeal carcinoma.
Zong JF; Liang QD; Lu QJ; Liu YH; Xu HC; Chen BJ; Guo QJ; Xu Y; Hu CR; Pan JJ; Lin SJ
BMC Cancer; 2021 Nov; 21(1):1274. PubMed ID: 34823489
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.
Cao SM; Yang Q; Guo L; Mai HQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Qiu F; Sun R; Chen QY; Huang PY; Luo DH; Hua YJ; Wu YS; Lv X; Wang L; Xia WX; Tang LQ; Ye YF; Chen MY; Guo X; Hong MH
Eur J Cancer; 2017 Apr; 75():14-23. PubMed ID: 28214653
[TBL] [Abstract][Full Text] [Related]
29. [Evaluation of induction chemotherapy with vinorelbine plus cisplatin (NP) or docetaxel plus cisplatin (TP) combined with concurrent chemoradiotherapy for patients with locally advanced nasopharyngeal carcinoma].
Han SH; Yu L; Zhang Z; Zhang PJ; Song HP; Guo CY
Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):623-6. PubMed ID: 24314223
[TBL] [Abstract][Full Text] [Related]
30. The value of the Prognostic Nutritional Index (PNI) in predicting outcomes and guiding the treatment strategy of nasopharyngeal carcinoma (NPC) patients receiving intensity-modulated radiotherapy (IMRT) with or without chemotherapy.
Miao J; Xiao W; Wang L; Han F; Wu H; Deng X; Guo X; Zhao C
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1263-1273. PubMed ID: 28247035
[TBL] [Abstract][Full Text] [Related]
31. The comparison of prognostic value of tumour volumetric regression ratio and RECIST 1.1 criteria after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
Zeng YY; Xiang ZZ; He T; Liu F; Shao BF; Yan RN; Ma JC; Wang XR; Liu L
Oral Oncol; 2020 Dec; 111():104924. PubMed ID: 32736209
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of concurrent chemoradiotherapy combined with nimotuzumab for low-risk T4 stage nasopharyngeal carcinoma: A pilot study.
Zhang S; Huang X; Zhou L; Lin S
Medicine (Baltimore); 2018 Sep; 97(38):e12503. PubMed ID: 30235761
[TBL] [Abstract][Full Text] [Related]
33. Improvement in quality of life in patients with nasopharyngeal carcinoma treated with non-invasive extracorporeal radiofrequency in combination with chemoradiotherapy.
Zhao C; Chen J; Yu B; Chen X
Int J Radiat Biol; 2014 Oct; 90(10):853-8. PubMed ID: 24758521
[TBL] [Abstract][Full Text] [Related]
34. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost.
Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C
Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757
[TBL] [Abstract][Full Text] [Related]
35. Home enteral nutrition may prevent myelosuppression of patients with nasopharyngeal carcinoma treated by concurrent chemoradiotherapy.
Li X; Zhou J; Chu C; You Q; Zhong R; Rao Z; Hu W
Head Neck; 2019 Oct; 41(10):3525-3534. PubMed ID: 31301097
[TBL] [Abstract][Full Text] [Related]
36. Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study.
Hong RL; Hsiao CF; Ting LL; Ko JY; Wang CW; Chang JTC; Lou PJ; Wang HM; Tsai MH; Lai SC; Liu TW
Ann Oncol; 2018 Sep; 29(9):1972-1979. PubMed ID: 30016391
[TBL] [Abstract][Full Text] [Related]
37. Association of osteopontin polymorphisms with nasopharyngeal carcinoma risk.
Wang J; Nong L; Wei Y; Qin S; Zhou Y; Tang Y
Hum Immunol; 2014 Jan; 75(1):76-80. PubMed ID: 24120738
[TBL] [Abstract][Full Text] [Related]
38. Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case-control study.
Li Y; Chen QY; Tang LQ; Liu LT; Guo SS; Guo L; Mo HY; Chen MY; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Shao JY; Sun Y; Tan J; Chen S; Ma J; Zhao C; Mai HQ
BMC Cancer; 2017 Aug; 17(1):567. PubMed ID: 28836950
[TBL] [Abstract][Full Text] [Related]
39. High expression of XPA confers poor prognosis for nasopharyngeal carcinoma patients treated with platinum-based chemoradiotherapy.
Fu X; Hu J; Han HY; Hua YJ; Zhou L; Shuai WD; Du WY; Kuang CM; Chen S; Huang W; Liu RY
Oncotarget; 2015 Sep; 6(29):28478-90. PubMed ID: 26156020
[TBL] [Abstract][Full Text] [Related]
40. Local and Lymph Node Relapse of Nasopharyngeal Carcinoma: A Single-Center Experience.
Toumi N; Ennouri S; Charfeddine I; Daoud J; Khanfir A
Ear Nose Throat J; 2021 Sep; 100(5_suppl):795S-800S. PubMed ID: 32141322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
